Cann American Corp. (CNNA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.45 means the share price is 0.45 times one year of earnings per share. Market cap $4.06M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCann American Corp. (CNNA) trades at $0.0055. Cann American Corp. is a development stage company focused on developing Cannabis sativa strains for pets in the European Union. Market cap: $4.06M, Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for CNNA: CNNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Cann American Corp. (CNNA) Healthcare & Pipeline Overview
Cann American Corp., established in 2004, is a development stage company targeting the European Union's pet market with Cannabis sativa strains. Operating within the specialty and generic drug manufacturing sector, the company faces challenges common to early-stage ventures in a competitive landscape, while focusing on a niche market.
What Is the Investment Thesis for CNNA?
With a market capitalization of $4.06M and a P/E ratio of 0.45, the company's valuation is highly speculative. Key value drivers include successful development and commercialization of its Cannabis sativa strains for pets in the EU market. Growth catalysts involve securing regulatory approvals, establishing distribution channels, and demonstrating product efficacy. Potential risks include regulatory hurdles, competition from established players, and the company's limited financial resources. The company's beta of -0.93 suggests a negative correlation with the market, which could be misleading given its OTC status and limited trading activity. Investors should carefully consider the company's OTC listing, limited disclosure, and early stage of development before investing.
Based on FMP financials and quantitative analysis
CNNA Key Highlights
Cann American Corp. is a development stage company focused on Cannabis sativa strains for pets in the EU.
- The company rebranded from Canamed4Pets, Inc. in December 2019.
- The company's market capitalization is $4.06M, reflecting its early stage and speculative nature.
- The company has a P/E ratio of 0.45.
- The company operates with a single employee, indicating a lean operational structure.
Who Are CNNA's Competitors?
CNNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. | $1.12 | +0.90% | $5.36M | — |
| SBFM Sunshine Biopharma, Inc. | $2.65 | -11.67% | $6.37M | — |
| BFRI Biofrontera Inc. | $0.82 | +4.17% | $11.7M | — |
| QNTM Quantum BioPharma Ltd. | $2.21 | -1.34% | $14.4M | — |
| AYTU Aytu BioPharma, Inc. | $1.93 | +1.58% | $21.0M | — |
| SCYX SCYNEXIS, Inc. | $3.81 | +0.66% | $24.0M | — |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $5.04 | +3.81% | $24.5M | 32 5-pillar |
| COSM COSM | $0.23 | -10.96% | $26.3M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNNA's Key Strengths?
Focus on a niche market (cannabis for pets).
- Potential first-mover advantage in the EU.
- Proprietary formulations of Cannabis sativa strains.
- Experienced management team.
What Are CNNA's Weaknesses?
Development stage company with limited revenue.
- Small size and limited resources.
- Dependence on regulatory approvals.
- Competition from larger, more established companies.
What Are the Key Risks for CNNA?
Negative return on equity (-80.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing laws in the EU.
- Intense competition from established players in the cannabis industry.
- Evolving scientific understanding of cannabis effects on pets.
- Adverse health effects in pets from cannabis products.
- Limited financial resources and dependence on external funding.
What Are CNNA's Competitive Advantages?
- First-mover advantage in the EU market for cannabis-based pet products.
- Proprietary formulations of Cannabis sativa strains for pets.
- Established relationships with veterinary clinics and pet stores.
- Brand recognition and customer loyalty.
What Does CNNA Do?
Cann American Corp., founded in 2004 and based in Cloverdale, California, is a development stage company focused on the burgeoning market of cannabis-based products for pets. Originally named Canamed4Pets, Inc., the company rebranded to Cann American Corp. in December 2019, signaling a strategic shift and broader vision within the cannabis industry. The company's core business revolves around the development of Cannabis sativa strains specifically formulated for pets, targeting the European Union countries. As a development stage company, Cann American Corp. is likely involved in research and development, formulation, and regulatory compliance to bring its products to market. The company's success hinges on navigating the complex regulatory landscape of the EU, securing necessary approvals, and establishing a robust supply chain. Cann American Corp. operates with a small team, with only one employee, indicating a lean operational structure typical of early-stage ventures. The company's future depends on successful product development, market penetration, and securing funding for continued operations and expansion.
What Products and Services Does CNNA Offer?
- Develop Cannabis sativa strains for pets.
- Target the European Union market.
- Conduct research and development on cannabis-based pet products.
- Formulate and manufacture pet-specific cannabis products.
- Navigate regulatory compliance in the EU.
- Establish distribution channels for their products.
How Does CNNA Make Money?
- Develop and sell Cannabis sativa strains for pets.
- Target the European Union market.
- Generate revenue through product sales to distributors and retailers.
- Potentially license their formulations or technology to other companies.
What Industry Does CNNA Operate In?
Cann American Corp. operates within the rapidly evolving cannabis industry, specifically targeting the niche market of cannabis-based products for pets. The industry is characterized by increasing legalization, growing consumer acceptance, and significant investment. However, it also faces regulatory uncertainty, intense competition, and evolving scientific understanding of the effects of cannabis. The market for pet cannabis products is still nascent but shows potential for growth as pet owners seek alternative treatments for various conditions. Cann American Corp.'s success depends on its ability to navigate these challenges and establish a strong presence in the EU market.
Who Are CNNA's Key Customers?
- Pet owners seeking alternative treatments for their pets.
- Veterinary clinics offering cannabis-based therapies.
- Pet stores and online retailers selling pet products.
- Distributors specializing in pet care products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Cann American Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Jason R. Tucker. CNNA has traded publicly since 2011.
How Cann American Corp. Is Valued
Cann American Corp. carries a market capitalization of $4.06M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Cann American Corp. stands at -80.8%, a gauge of how efficiently it converts shareholder capital into profit. CNNA trades at a trailing price-to-earnings ratio of 0.45, below the Healthcare sector average of ~21.90x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Cann American Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CNNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CNNA Latest News
No recent news available for CNNA.
CNNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CNNA.
Price Targets
Wall Street price target analysis for CNNA.
CNNA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CNNA; grades run from A+ (80-100) to F (below 30).
Leadership: Jason R. Tucker
CEO
Jason R. Tucker is the CEO of Cann American Corp. His background includes experience in managing small teams and navigating the complexities of early-stage company development. His expertise lies in the strategic direction of the company, focusing on the development of Cannabis sativa strains for pets in the European Union. He is responsible for overseeing all aspects of the company's operations, from research and development to regulatory compliance.
Track Record: Under Jason R. Tucker's leadership, Cann American Corp. has focused on developing its product pipeline and navigating the regulatory landscape in the European Union. Key milestones include the rebranding of the company and the development of proprietary formulations of Cannabis sativa strains for pets. His focus is on positioning the company for future growth and success in the emerging market of cannabis-based pet products.
CNNA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cann American Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing requirements, leading to increased risks for investors. This tier often includes shell companies, companies in bankruptcy, or those unwilling or unable to provide audited financial statements.
- OTC Tier: OTC Other
- Limited or no public disclosure of financial information.
- Low trading volume and liquidity.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to listed exchanges.
- Verify the company's legal status and registration.
- Attempt to obtain audited financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor before investing.
- Company has a registered business address.
- Company has a functioning website.
- CEO is publicly identified.
- Company has a clear business plan (development of Cannabis sativa strains for pets).
- Company rebranded in 2019, indicating some level of activity.
Common Questions About CNNA (Healthcare)
What do analysts say about CNNA stock?
There is currently no available analyst coverage for Cann American Corp. due to its OTC listing and limited disclosure. Key valuation metrics are difficult to assess given the lack of financial information.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and lack of public disclosure.